Noemi Reguart, Medical Oncologist at Hospital Clinic Barcelona, shared a post on X:
“HARMONi-6: Ivos/ChT vs ChT/IO in 1L advanced sq-NSCLC
- mPFS 11.14 vs 6.9 mo HR 0.60 –
- Higher ORR and mDOR
- Low VEGF-rel AEs
First phase 3 study to improve PFS outcomes compared to SoC- will this translate to an OS improvement?
Benefit in all PD-L1 expression levels.”
Follow the latest ESMO 2025 news on OncoDaily.
